NEIL DAVIE, Ph.D.
GLOBAL THERAPEUTIC AREA HEAD
Neil Davie is Global Therapeutic Area Head, Pulmonary Hypertension, leading the therapeutic area’s strategy and portfolio execution, including clinical development, He has extensive experience as a drug developer leading projects across multiple therapeutic areas, particularly in specialty/rare diseases with high unmet medical need. He has held leadership roles with increased responsibility allied with strategic pharmaceutical drug development across early and late programs in the area of pulmonary, neurology, immunology and hematology.
Prior to joining Janssen in October 2019, Neil worked at UCB Pharma as Development Lead with responsibility and accountability for their innovative subcutaneous anti-FcRn monoclonal antibody platform, rozanolixizumab. Prior to this, he spent five years at Bayer as Vice President of Clinical Development responsible for the development of riociguat (Adempas) in chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH); he successfully represented Bayer at the FDA Advisory Committee, leading to the approval of Adempas in both indications. Before joining Bayer, he was Senior Medical Director in the Pulmonary Vascular Development Group at Pfizer, working on Revatio (sildenafil citrate) for PAH and additional rare diseases. Previously he was at Encysive Pharmaceuticals, where he was Director of Scientific Affairs for the launch of Thelin (sitaxentan sodium) for PAH in Europe, Australia and Canada.
Neil obtained his BSc. in Human Biology from the University of Leeds and his Ph.D. in Pulmonary Pharmacology from Imperial College London. He completed a post-doctoral fellowship at the University of Colorado Health Sciences Center (Stenmark Lab), in the field of pulmonary hypertension. He was appointed Assistant Professor of Pediatric Cardiology at the Children’s Hospital in Denver, working in the pulmonary hypertension lab of Dunbar Ivy. Previously, he held the post of Visiting Professor of Cellular & Respiratory Medicine at the University of Newcastle, working with Professor Paul Corris.